A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Recombinant Human Arginase 1 (rhArg1)is
safe and effective in the treatment of patients with Relapsed or Refractory Leukemia or
Lymphoma.